These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 31537075)

  • 1. Effect of Botulinum toxin A application in neuro-ophtalmologic indications on Schirmers test and tears osmolarity.
    Žiak P; Halička J; Kapitánová K; Mojžiš P
    Cesk Slov Oftalmol; 2019; 75(2):74-77. PubMed ID: 31537075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the effects of Botulinum Toxin A on tear metrics in patients with hemifacial spasm.
    Mali YP; Schultze RL; Wladis EJ
    Orbit; 2017 Oct; 36(5):307-310. PubMed ID: 28627956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Results of long term treatment of essential blepharospasm and facial hemispasm with botulinum toxin A].
    Ziak P
    Cesk Slov Oftalmol; 2004 Jan; 60(1):37-44. PubMed ID: 15011305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Lacrimal film evaluation of patients with facial dystonia during botulinum toxin type A treatment].
    Costa PG; Cardoso IP; Saraiva FP; Raiza AC; Tanaka LK; Matayoshi S
    Arq Bras Oftalmol; 2006; 69(3):319-22. PubMed ID: 16936952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.
    Ababneh OH; Cetinkaya A; Kulwin DR
    Clin Exp Ophthalmol; 2014 Apr; 42(3):254-61. PubMed ID: 23844601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corneal and Tear Film Changes After Botulinum Toxin-A in Blepharospasm or Hemifacial Spasm.
    Gunes A; Demirci S; Koyuncuoglu HR; Tok L; Tok O
    Cornea; 2015 Aug; 34(8):906-10. PubMed ID: 26075455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tear osmolarity, dry eye syndrome, blepharospasm and botulinum neurotoxin.
    Girard B; de Saint Sauveur G
    J Fr Ophtalmol; 2021 Dec; 44(10):1553-1559. PubMed ID: 34756743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tear production and drainage after botulinum toxin A injection in patients with essential blepharospasm.
    Park DI; Shin HM; Lee SY; Lew H
    Acta Ophthalmol; 2013 Mar; 91(2):e108-12. PubMed ID: 23425111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Essential blepharospasm and hemifacial spasm: characteristic of the patient, botulinum toxin A treatment and literature review].
    Schellini SA; Matai O; Igami TZ; Padovani CR; Padovani CP
    Arq Bras Oftalmol; 2006; 69(1):23-6. PubMed ID: 16491229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Botulinum toxin type A influence on the lacrimal function of patients with facial dystonia].
    Oliveira FC; Oliveira GC; Cariello AJ; Felberg S; Osaki MH
    Arq Bras Oftalmol; 2010; 73(5):405-8. PubMed ID: 21225122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of botulinum toxin in neuro-ophthalmology.
    O'Day J
    Curr Opin Ophthalmol; 2001 Dec; 12(6):419-22. PubMed ID: 11734681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocular surface status in patients with hemifacial spasm under long-lasting treatment with botulinum A toxin: A comparative fellow eye study.
    Pellegrini M; Schiavi C; Taroni L; Sebastiani S; Bernabei F; Roda M; Moscardelli F; Giannaccare G
    Indian J Ophthalmol; 2019 Sep; 67(9):1405-1409. PubMed ID: 31436182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tear meniscus, corneal topographic and aberrometric changes after botulinum toxin-a injection in patients with blepharospasm and hemifacial spasm.
    Bayraktar Bilen N; Bilen Ş; Topçu Yılmaz P; Evren Kemer Ö
    Int Ophthalmol; 2022 Aug; 42(8):2625-2632. PubMed ID: 35355169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye.
    Horwath-Winter J; Bergloeff J; Floegel I; Haller-Schober EM; Schmut O
    Br J Ophthalmol; 2003 Jan; 87(1):54-6. PubMed ID: 12488263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm.
    Jost WH; Kohl A
    J Neurol; 2001 Apr; 248 Suppl 1():21-4. PubMed ID: 11357234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of carbamazepine combined with botulinum toxin a in the treatment of blepharospasm and hemifacial spasm.
    Li XH; Lin SC; Hu YF; Liu LY; Liu JB; Hong YC
    Eye Sci; 2012 Dec; 27(4):178-81. PubMed ID: 23225838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose treatment of cervical dystonia, blepharospasm and facial hemispasm with albumin-diluted botulinum toxin type A under EMG guidance. An open label study.
    Rollnik JD; Matzke M; Wohlfarth K; Dengler R; Bigalke H
    Eur Neurol; 2000; 43(1):9-12. PubMed ID: 10601802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of two different formulations of botulinum toxin A for the treatment of blepharospasm and hemifacial spasm.
    Wu CJ; Shen JH; Chen Y; Lian YJ
    Turk Neurosurg; 2011; 21(4):625-9. PubMed ID: 22194126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox.
    Badarny S; Susel Z; Honigman S
    Isr Med Assoc J; 2008 Jul; 10(7):520-2. PubMed ID: 18751631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Riolan's muscle: action and indications for botulinum toxin injection.
    Mackie IA
    Eye (Lond); 2000 Jun; 14 ( Pt 3A)():347-52. PubMed ID: 11026998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.